Nuwellis NUWE
Nuwellis FY 2021: revenue $7.9M, up 6%; diluted EPS −$525,964,696.22
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001140361-22-007694
- Document
- 10-K
Key figures from this report
These are the numbers Nuwellis reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$7.9M+6% from $7.4M in FY 202010-K income statement, on EDGAR
- Net income−$19.6MAgainst −$15.8M in FY 202010-K income statement, on EDGAR
- Diluted EPS−$525,964,696.22Against −$1,955,415,787.00 in FY 2020. Split-adjusted, as the tables show it; the filing reported −$2.8710-K income statement, on EDGAR
- Cash and cash equivalents$24.2M+68% from $14.4M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$17.9MAgainst −$16.6M in FY 202010-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.
- Glucotrack GCTK public float $5M, Jun 30, 2025
- Catheter Precision VJET public float $4M, Jun 30, 2025
- Aethlon Medical AEMD public float $6M, Sep 30, 2025
- STRATA Skin Sciences SSKN public float $4M, Jun 30, 2025
- Encision ECIA
